Investigational drug · Phase 3
Etoricoxib fixed dose
Also called: Etori
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gout Arthritis, Gout Attack, Acute Low-back Pain.
Phase 3Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
11
Any phase or sponsor naming "Etoricoxib fixed dose"
First trial start
2024
Sep 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Etoricoxib fixed dose", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gout Arthritis
- Gout Attack
- Acute Low-back Pain
- Muscle Spasm; Back Pain
Approved drugs for the same conditions: Gout · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "Etoricoxib fixed dose" as an intervention, largest first.
- PECS-2 for Breast SurgeryPivotal-lookingCompleted
Umeå UniversityAcademic, hospital or other
NCT03117894 · 200 participants · Start May 23, 2017 · Primary completion Oct 22, 2020
Drug: Ropivacaine 5 mg/ml, 35 ml; Remifentanil 50 microg/ml and 6 more · For: Breast Neoplasm Female; Regional Anesthesia; Anesthesia and 2 more
Sites: Östersund, Sweden
- Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back PainPivotal-lookingCompleted
Laboratorios Silanes S.A. de C.V.Industry
NCT06517823 · 190 participants · Start Apr 26, 2024 · Primary completion Oct 4, 2024
Drug: Etoricoxib + Cyanocobalamin fixed dose; Etoricoxib fixed dose · For: Acute Low-back Pain
Sites: Mexico City, Mexico
- Assessing the Benefits of Dry Needling for Low Back Pain When Combined With Regular TreatmentPivotal-lookingCompleted
Dr. Vishwanath Karad MIT World Peace UniversityAcademic, hospital or other
NCT06791434 · 156 participants · Start Aug 30, 2024 · Primary completion Aug 26, 2025
Drug: Fixed Dose Combination "Etoshine MR" tablets · For: Low Back Pain
Sites: Pune, India
- Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle SpasmPivotal-lookingCompleted
Laboratorios Silanes S.A. de C.V.Industry
NCT06863662 · 136 participants · Start Sep 18, 2024 · Primary completion Sep 26, 2025
Drug: Etoricoxib + Tizanidine fixed dose; Etoricoxib fixed dose · For: Acute Low-back Pain; Muscle Spasm; Back Pain
Sites: Mexico City, Mexico
- Efficacy and Safety of Fixed-dose Combination of Etoricoxib/Tramadol vs Acetaminophen/Tramadol for Acute Low Back PainPivotal-lookingCompleted
Laboratorios Silanes S.A. de C.V.Industry
NCT04968158 · 124 participants · Start Nov 29, 2021 · Primary completion Mar 15, 2022
Drug: Etoricoxib 90 mg / Tramadol 50 mg; Acetaminophen 325 mg / Tramadol 37.5 mg · For: Acute Low Back Pain
Sites: Mexico City, Mexico
- Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and SynovitisPivotal-lookingCompleted
Laboratorios Silanes S.A. de C.V.Industry
NCT07328022 · 89 participants · Start May 14, 2025 · Primary completion Aug 20, 2025
Drug: Fixed Dose Etoricoxib + Betamethasone; Monotherapy Etoricoxib · For: Bursitis; Tendinitis; Synovitis
Sites: Mexico City, Mexico
- Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout ArthritisPivotal-lookingRecruiting
Laboratorios Silanes S.A. de C.V.Industry
NCT06863701 · 72 participants (planned) · Start Jan 27, 2025 · Primary completion Dec 31, 2026
Drug: Etoricoxib + Betamethasone fixed dose; Etoricoxib fixed dose · For: Gout Arthritis; Gout Attack
Sites: Mexico City, Mexico
Laboratorios Silanes S.A. de C.V.Industry
NCT05533073 · 42 participants · Start Aug 3, 2020 · Primary completion Sep 7, 2020
Drug: A1: Etoricoxib / Tramadol Fixed dose combination; A2: Etoricoxib and 1 more · For: Healthy
Sites: Mexico City, Mexico
Laboratorios Silanes S.A. de C.V.Industry
NCT07454369 · 42 participants · Start Oct 24, 2022 · Primary completion Nov 25, 2022
Drug: A1: Etoricoxib / Betamethasone in fixed dose combination tablet. (Laboratorios Silanes S.A. de C.V.); A2: Etoricoxib (Arcoxia®, Laboratorios Schering-Plough, S.A. de C.V.) and 1 more · For: Healthy
Sites: Monterrey, Mexico
- Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164)Pivotal-lookingWithdrawn
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01979510 · 0 participants · Start Nov 2013 · Primary completion May 2014
Drug: MK-0663B; DOLOCAM PLUS® and 1 more · For: Low Back Pain
Newest research
PubMed records naming it or its code names, newest first.
- COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Majchrzak-Celiska A, Misiorek JO, Kruhlenia N, et al. · BMC Cancer 2021
Also in development for Gout Arthritis
- EtoricoxibPhase 34 trials
Laboratorios Silanes S.A. de C.V. · Gout Arthritis, Gout Attack, Acute Low-back Pain
- SSGJ-613Phase 21 trial
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Gout Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.